海外登壇者

Dr. Ozmen serves as a breast surgical oncologist at Massachusetts General Hospital and holds the position of Assistant Professor of Surgery at Harvard Medical School. He graduated from Istanbul University, Istanbul Medical faculty in 2007. He completed his initial surgery residency at Marmara University School of Medicine (Istanbul, Turkey) in 2013 before joining the faculty there. He, then, completed “Breast Surgical Oncology Fellowship” at University of Miami, Miller School of Medicine, in 2018. He completed a second surgery residency at the same institution in 2022 and has been working since then at Massachusetts General Hospital. He has conducted many award-winning breast cancer studies, which were published in well-known journals and worked as associate editor in breast cancer textbooks. His areas of research are breast cancer related lymphedema and application of AI in breast cancer diagnosis and treatment. He speaks nationally and internationally on breast cancer, and also serves on relevant professional societies.

Prof. Giampaolo Bianchini is Associate Professor at Università Vita-Salute San Raffaele and the Head of Breast Oncology at the Department of Medical Oncology of the IRCCS San Raffaele Hospital.
After graduating in Medicine and Surgery in 2000 from the University of Milan-Bicocca, he specialised in Medical Oncology in 2004 at the University of Milan. During his training, he was a Visiting Scientist at several prestigious American institutions, such as the National Cancer Institute (Bethesda), MD Anderson Cancer Center (Houston) and Yale Cancer Center (New Haven).
Prof. Giampaolo Bianchini is also head of the clinical translational and immunotherapy research group at the Department of Medical Oncology and is involved in numerous research projects aimed at women with breast cancer to understand the mechanisms of response and resistance to available drugs, the identification of new therapeutic strategies and the definition of biomarkers useful to improve the personalization of treatments.
Prof. Bianchini has authored numerous publications in international journals such as Nature, Lancet, Nature Review Clinical Oncology, Journal Clinical Oncology, Lancet Oncology, Cancer Cell, Annals of Oncology, JAMA Oncology and many others. He constantly participates in national and international congresses and conferences.

Mehra Golshan, MD, MBA, is a cancer surgeon and a nationally and internationally recognized leader in breast cancer treatment and research. In addition to caring for patients, he serves as Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center.
Dr. Golshan also serves as the Executive Vice Chair of Operations in the Department of Surgery and Interim Vice Chair of Education and Professor of Surgical Oncology at the Yale School of Medicine.
Dr. Golshan is a leader in the research with over 150 peer reviewed publications. He has led numerous Phase I, II and III clinical trials and translational science innovations impacting the treatment options and outcomes for women. He is an innovator in tailoring surgery and therapy for women with early stage breast cancer with funding support from the Breast Cancer Research Foundation and National Institutes of Health. He is the principal investigator of several phase II trials aiming to reduce the need for second surgeries or re-excisions in women with breast cancer, one of which uses innovative image-guided operating room capabilities to capture and remove all residual tumor utilizing MRI and mass spectrometry which is used at Yale’s hybrid operating room.
Dr. Golshan prides himself on being an educator having trained and mentored over a hundred breast surgical fellows as well as international surgeons. He has lectured and taught surgeons, trainees and students nationally and internationally in the field of oncology and breast cancer treatment.
Dr. Golshan is a Board Member of the National Accreditation Program for Breast Centers (NAPBC), Chair of NAPBC Education Committee and Chair of the American College of Surgeons Committee on Interprofessional Education and Practice.
Dr. Golshan completed his fellowship in breast surgical oncology at Northwestern Memorial Hospital. He earned his Medical Degree from Case Western Reserve University School of Medicine and an MBA at Massachusetts Institute of Technology, Sloan School of Management in Cambridge Massachusetts.
Prior to joining Yale, he spent 17 years in Boston at Harvard’s Brigham and Women’s Hospital, Dana Farber Cancer Institute where he was the inaugural and incumbent Dr. Abdul Mohsen and Sultana Al-Tuwaijri Distinguished Chair in Surgical Oncology. He also served as the Director of the Breast Surgical Oncology Fellowship at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Massachusetts General Hospital and was an Associate Professor of Surgery at Harvard Medical School.

Prof. Park is a breast surgeon and surgical oncologist currently working as a Professor in the Department of Surgery at Yonsei University College of Medicine.
He is one of the pioneers in robot mastectomy. He began performing the robotic mastectomy using cadaveric samples in 2013. He performed the first human case of a robot mastectomy in Asia in 2016. He developed a gasless technique of robot mastectomy and was the first to publish a paper describing it. He also performed the first robot mastectomy and robotic axillary lymph node dissection using the new da Vinci SP system in 2018 and 2019, respectively. He is actively applying robotic surgical systems in mastectomy and/or axillary lymph node dissection for women with breast cancer or BRCA1/2 mutations. He is one of the high-volume surgeons in his country performing over 500 breast surgeries in 2018. His team at Severance Hospital performed over 200 cumulative cases of robotic mastectomy in 2020.
He is actively participating in the clinical trial group of the Korean Breast Cancer Society.
He established the Korea Robot-Endoscopy & Minimal Access Breast Surgery Study Group (KoREa-BSG) and the director of general affairs of the group. He has published over 70 scientific articles in the literature, conducted numerous lectures as an invited speaker in many scientific conferences, and he wrote several chapters of a textbook of breast oncology in Korea. His research interests include robot breast surgery, oncoplastic breast surgery, surgical oncology, minimally invasive surgery, endocrine surgery, biostatistics, preclinical models, and genomics.

Current position (since July 2022): Chief Physician of the Senologic Department and Chairman of the Interdisciplinary Breast Cancer Center in Osnabrueck, Germany, teaching hospital of the University Hospital Muenster, Germany

Private Practice: Breast Cancer Center Osnabrueck / Department of Senology, Franziskus-Hospital Harderberg, Niels-Stensen-Kliniken, Alte Rothenfelder Straße 23, 49124 Georgsmarienhuette, Germany

Academic title: PD Dr. med.

Medical education: Medical Gynecologist and Specialist for Breast Cancer Diagnosis and

Treatment Previous appointments: 2009 - 2022 Medical physician at the Department of Gynecology and Obstetrics and Breast Cancer Center, University Hospital Schleswig-Holstein, Campus Kiel

Experience in conduction of clinical trials: Since 2009

Experience in conduction of basic research: Since 2007

Memberships:
Senologic International Society (SIS)
European Society of Medical Oncology (ESMO)
German society of Senology (DGS)
German cancer society (DKS)
German society of Gynecology and Obstetrics (DGGG)
German Work Group of Gynecologic Oncology (AGO Mamma)
German society of ultrasound in medicine (DEGUM)

[Educational Background]
■2007-2009 Ph.D. Graduate School,l Ulsan University, Seoul, Korea
■2004-2006 M.S. Graduate School, Ulsan University, Seoul, Korea
■1996-2000 M.D. College of Medicine
Cheon Buk National University, Cheon Ju, Korea
■1994-1996 Premedical Course College of Natural Sciences
Cheon Buk National University, Cheon Ju, Korea

[Work Experience]
■Mar. 2022-present Professor
College of Medicine, University of Ulsan
Asan Medical Center, Seoul, Korea
■Mar. 2016-Feb.2022 Associate Professor
College of Medicine, University of Ulsan
Asan Medical Center, Seoul, Korea.
■Mar.2010-Feb.2016 Clinical Assistant Professor
College of Medicine, University of Ulsan
Asan Medical Center, Seoul, Korea.
■Sep. 2010 Visiting doctor
Dana Farber Harvard Medical School
Memorial sloan kettering cancer center
■Mar. 2001-Feb.2010 Resident, Fellow, Clinical Instructor
College of Medicine, University of UlsanAsan Medical Center, Seoul, Korea.

[Publications]
■Age-Related Incidence and Peak Occurrence of Contralateral Breast Cancer
JAMA Netw Open. 2023 Dec 01
■Factors in Parenting Stress in Young Patients With Breast Cancer and Implications for Children's Emotional
Development: The PSYCHE Study
JAMA Netw Open. 2023 Nov 01
■Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma
JAMA Netw Open, 2023 Nov 01
■Survival After Development of Contralateral Breast Cancer in Korean Patients With Breast Cancer
JAMA Netw Open. 2023 Sep 14
■Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor–Positive Breast
Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
J Clin Oncol. 2023 Aug 22
■Surgical Treatment after Neoadjuvant Systemic Therapy in Young Women with Breast Cancer: Results from a Prospective Cohort Study.
AnnSurg. 2020 Dec 23

※Besides JAMA Network Open, Journal of Clinical Oncology, annals of surgery, published 163 SCI and SCIE

[Educational Background]
MD: Yonsei University College of Medicine, Seoul, Korea (2003-2009, Medicine)
MS: Yonsei University College of Medicine, Seoul, Korea (2014-2018, Surgery)
PhD: Hanyang University College of Medicine, Seoul, Korea (2020-2023, Surgery)

[Work Experience]
Clinical fellow, Department of Surgery, Gangnam Severance Hospital, Seoul, Korea (2018-2020)
Clinical Assistant Professor, Hanyang University Hospital, Seoul, South Korea (2020-2023)
Assistant Professor, Hanyang University College of Medicine, Seoul, South Korea (2023-present)
Member of Korean Breast Cancer Study Group (KBCSG), Korean Breast Cancer Registry (KBCR) & Statistics Committee (2020 - present)

[Publications]
Prognostic Implication of YY1 and CP2c Expression in Patients with Primary Breast Cancer (Cancers, 2023)
Survival benefit from axillary surgery in patients aged 70 years or older with clinically node-negative breast cancer: a population-based propensity-score matched analysis (EJSO, 2022)
Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer (International Journal of Cancer, 2021)
Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index (Scientific Reports, 2020)
Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy (Breast Cancer Research and Treatment, 2020)

[Awards]
Merit Award, ESMO Asia Congress (2019)
Research Grant from the Korean Surgical Society (2022)
Good Poster Presentation, Global Breast Cancer Conference (2022)
Media Award for Professor, Hanyang University Hospital (2023)

[Educational Background]
Mar 2006 ~ Feb 2012 Bachelor of Science in Mechanical and Aerospace engineering
Seoul National University, College of Engineering, Seoul, Korea
Mar 2006 ~ Feb 2012 Medical Doctor
Chung-Ang University, College of Medicine, Seoul, Korea

[Work Experience]
Mar 2017 ~ Feb 2021 Residency, Department of General Surgery, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea
Mar 2021 ~ Feb 2024 Fellowship, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Mar 2024 ~ Clinical Assistant Professor, Division of Breast Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

[Publications]
1) Lee J, Lee YJ, Bae SJ, Baek SH, Kook Y, Cha YJ, Lee JW, Son BH, Ahn SH, Lee HJ, Gong G, Jeong J, Lee SB, Ahn SG.
Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer. JAMA Netw Open. 2023 Aug 1;6(8):e2330961.
2) Lee YJ, Yoo TK, Kim J, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH, Ahn SH, Lee SB. Survival outcomes of breast cancer patients with recurrence after surgery according to period and subtype. PLoS One. 2023 Jul 27;18(7):e0284460.
3) Lee YJ, Jeong JH, Jung J, Yoo TK, Lee SB, Kim J, Ko BS, Kim HJ, Lee JW, Son BH, Chung IY. Waiting Time for Breast Cancer Treatment in Korea: A Nationwide Cohort Study. J Breast Cancer. 2023 Aug;26(4):334-343.
4) Wu ZY, Lee YJ(co-first author), Kim H, Lee J, Chung IY, Kim J, Lee S, Son BH, Kim SB, Jeong JH, Gong G, Ahn SH, Ko B. Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer. Front Oncol. 2021 Apr 28;11:665426.
5) Lee YJ, Wu ZY, Kim HJ, Lee JW, Chung IY, Kim J, Lee SB, Son BH, Kim SB, Jung JH, Gong G, Ahn SH, Ko B. Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen. J Breast Cancer. 2020 Oct;23(5):553-559.
6) Lee YW, Ahn SH, Lee YJ, Yoo TK, Kim J, Chung IY, Kim HJ, Ko BS, Lee JW, Son BH, Lee SB. Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer. PLoS One. 2023 Aug 17;18(8):e0290174.
7) Kang YJ, Oh SJ, Bae SY, Kim EK, Lee YJ, Park EH, Jeong J, Park HK, Suh YJ, Kim YS. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Sci Rep. 2023 Jul 7;13(1):11008.
8) Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sanchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berliere M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. JAMA. 2024 Jan 2;331(1):49-59.

[Awards]
2020 “Professor Seung Kyu Lee’s Development Fund Award”, Asan Medical Center
2021 “Best Free Paper Presentation Award (Encourage Award)”, The Korean society of 3D Printing in Medicine
2023 “Outstanding Fellow of the Year”, Department of Surgery, Asan Medical Center
2024 “Hospital President’s Commendation”, Asan Medical Center

[Educational Background]
1998-2002 M.D., College of Medicine, Seoul National University, Seoul, Korea
2004-2007 M.S., College of Medicine, Seoul National University, Seoul, Korea
2007-2016 Ph.D., College of Medicine, Seoul National University, Seoul, Korea

[Work Experience]
2011-2016 Assistant Professor,
2016-2021 Associate Professor,
2021-current Professor,
Division of Hematology and Medical Oncology,
Department of Internal Medicine,
Seoul National University Hospital, Seoul, Korea

Publications
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 Aug 23;379(8):753-763.

Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, Ueno T, Kwong A, Li H, Huang SH, Leung R, Han W, Tan B, Hu FC, Huang CS, Cheng AL, Lu YS, Asian Breast Cancer Cooperative Group. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. J Natl Cancer Inst. 2019 Dec 1;111(12):1298-1306.

Min A, Jang H, Kim S, Lee KH, Kim DK, Suh KJ, Yang Y, Elvin P, O'Connor MJ, Im SA. Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response. Mol Cancer Ther. 2018 Dec;17(12):2507-2518